Preclinical Research

  • Preclinical Research
  • :root { --primary-green: #00685e; --button-green: #009867; --dark-green: #004d40; --light-green: #e0f2f1; --text-dark: #333; --text-light: #fff; --light-purple: #e4ebf5; --accent-green: #4db6ac; } .container { max-width: 1040px; margin: 0 auto; background-color: #fff; box-shadow: 0 0 20px rgba(0, 0, 0, 0.1); } .text-intro { text-align: center; font-size: 1.2em; padding: 0 4rem 0 4rem; } /* Header */ /* Header */ header { pad
    The 76th annual AALAS meeting took place in the Long Beach Convention Center, CA

    The 76th annual American Association for Laboratory Animal Science (AALAS) National Meeting is a cornerstone event for the laboratory animal science community, bringing together researchers, veterinarians, technicians, and industry partners to share knowledge, i

    The 2025 American College of Toxicology (ACT) Annual Meeting was held in Phoenix, AZ

    The American College of Toxicology (ACT) Annual Meeting continues to be my favorite scientific event of the year, and for good reason.

    Drug developers and scientists are constantly looking for animal models that are cost effective, aligned with research goals, and allow for lower test article (TA) usage without sacrificing scientific integrity and regulatory approval

    In Issue 47 of The Altascientist, we take a closer look at what makes the Sinclair Nanopig® a scientifically appropriate and cost-effective non-rodent species for your preclinical programs, covering:

    • the benefits and advantages of using minipig models
    • test article usage comparison between Sinclair Nanopig® and canine models
    • the history and regulatory acceptance of the Sinclair Nanopig®
    • a case study on reduced emesis in the Sinclair Nanopig®

    Minipigs in Preclinical Drug Development

    In the continuum of preclinical drug development, the selection of appropriate animal models is crucial for providing the safety data that is required for a novel therapeutic to progress into clinical trials.

    Over the past three decades, drug development has evolved rapidly—driven by new technologies, tighter timelines, and greater collaboration. CROs like Altasciences have transformed, shifting from service providers to strategic partners.

    As a board-certified toxicologist and experienced Good Laboratory Practices (GLP) Consultant, I spend quite a bit of time advising on quality issues of New Approach Methodologies (NAMs) in support of toxicology programs. While these alternative methods are exciting and full of promise, they come with their own set of challenges. 

    STAT: Responsible AI Frees Scientists to Focus on Science

    Subscribe to Preclinical Research